MDGL Q3 2020 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$59M

Net Income

-$58M

EPS (Diluted)

$-3.75

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$48M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$340M

Total Liabilities

$50M

Stockholders' Equity

$290M

Cash & Equivalents

$109M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$28,000	+100.0%
Operating Income	-$59M	-$24M	-143.0%
Net Income	-$58M	-$21M	-170.5%